FDA-approved
Sexual & reproductive
Ganirelix
Evidence
FDA approved
Class
GnRH antagonist
KEY TAKEAWAY
Ganirelix is a ten-amino-acid synthetic GnRH antagonist used in fertility treatment. The FDA approved ganirelix in 1999 to prevent premature luteinizing hormone surges in women having controlled ovarian hyperstimulation.
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH antagonist
Approved for
Preventing early ovulation during fertility treatment
Key fact
The FDA approved ganirelix in 1999 to prevent premature luteinizing hormone surges in women having controlled ovarian hyperstimulation.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Ganirelix is a ten-amino-acid synthetic GnRH antagonist used in fertility treatment.
It blocks GnRH receptors in the pituitary gland, which prevents a premature surge of luteinizing hormone.
The FDA approved ganirelix in 1999 to prevent premature luteinizing hormone surges in women having controlled ovarian hyperstimulation.
Preventing early ovulation during fertility treatment.
Abdominal pain, headache and injection-site reactions are reported. Ovarian hyperstimulation syndrome can occur.
U.S. FDA prescribing information for Ganirelix. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.